“Reduced Dosing Frequency With Tralokinumab Provides Sustained Improvements in Symptoms and Quality of Life Up to 1 Year in Adults With Moderate-to-Severe AD”, J of Skin, vol. 10, no. 2, p. s731, Mar. 2026, doi: 10.25251/26swpe94.